AU Patent

AU2014339221A1 — Crystalline solvate forms of Cabazitaxel

Assigned to Indena SpA · Expires 2016-05-12 · 10y expired

What this patent protects

The present invention relates to new crystalline forms of Cabazitaxel of formula (I). Specifically, the present invention provides four new crystalline solvate forms of Cabazitaxel, designated as form S2 (solvate with 2-methyltetrahydrofuran), form S4 (solvate with

USPTO Abstract

The present invention relates to new crystalline forms of Cabazitaxel of formula (I). Specifically, the present invention provides four new crystalline solvate forms of Cabazitaxel, designated as form S2 (solvate with 2-methyltetrahydrofuran), form S4 (solvate with

Drugs covered by this patent

Patent Metadata

Patent number
AU2014339221A1
Jurisdiction
AU
Classification
—
Expires
2016-05-12
Drug substance claim
No
Drug product claim
No
Assignee
Indena SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.